Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study to Assess the Safety, Tolerability and PK of Ceftazidime-Avibactam in Healthy Chinese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Provision of signed and dated, written informed consent prior to any study-specific procedures.~* Healthy male and female (of non-child bearing potential) Chinese subjects, with suitable veins for cannulation or repeated venipuncture~* BMI 19 to 24 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg.~Key Exclusion Criteria:~* Any clinical condition requiring the regular use of any medication.~* Consumption of alcohol, drug, tobacco (cigarettes).~* Sensitive to any food, or any serious reaction to carbapenem, cephalosporin, or other β-lactam antibiotics.~* Severe medical or psychiatric condition or laboratory abnormality.~* Blood donation.~* 12 lead ECG abnormal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): IV infusions of 0.9% normal saline
- CAZ-AVI (Type: EXPERIMENTAL): IV infusion of AVI 500 mg + CAZ 2000 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).